Development of a Succinate-Modulating Enzyme for Metabolic and Inflammatory Diseases

Identifier:  TFG:8982

Handle: https://hdl.handle.net/20.500.11797/TFG8982

Authors:  González Lozano, Nuria

Abstract:
Succinate, a key metabolic intermediate, is elevated in non-alcoholic fatty liver disease (NAFLD) and inflammatory bowel disease (IBD), contributing to their progression. We investigated succinate-degrading enzymes (SD1, and 2 SD1 variants) as potential therapies. In NAFLD mice, SD1 and a variant showed good responses, while in the DSS-induced IBD model, SD1 reduced inflammation in the acute model, but had limited effect in relapse. Enzyme production was also optimized. Results partially supported our hypothesis, highlighting therapeutic potential. However, there’s still the need for further research to improve treatment strategies, mostly for IBD relapse.